DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Oteracil is an investigational drug.
There have been 72 clinical trials for Oteracil. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2013.
The most common disease conditions in clinical trials are Stomach Neoplasms, Pancreatic Neoplasms, and Carcinoma. The leading clinical trial sponsors are Fudan University, Taiho Oncology, Inc., and Quintiles, Inc.
There are eighty-six US patents protecting this investigational drug and eight hundred and thirty international patents.
Recent Clinical Trials for Oteracil
|A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer||Lee's Pharmaceutical Limited||Phase 2|
|Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)||Yu jiren||Phase 2|
|Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer||ACT Genomics||Phase 2|
Top disease conditions for Oteracil
Top clinical trial sponsors for Oteracil
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Oteracil||Start Trial||Chromane herbicides||E. I. Du Pont de Nemours and Company (Wilmington, DE)||Start Trial|
|Oteracil||Start Trial||Composition and method for inhibiting inflammation caused by non-parenteral administration of 5-fluorouracil type compounds||Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)||Start Trial|
|Oteracil||Start Trial||Salts of optically active 4-hydroxy-8(3-lower alkoxy-4-phenylsulfinylphenyl)pyrazolo(1,5-A)-1,3,5- triazines and a process for production thereof||Otsuka Pharmaceutical Factory, Inc. (Tokushima, JP)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|